Dipna Pharmachem Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 7, 2025, 10:34 pm

Market Cap	31.9 Cr.
Current Price	13.3
High / Low	16.6/6.40
Stock P/E	38.4
Book Value	15.8
Dividend Yield	0.00 %
ROCE	7.05 %
ROE	3.52 %
Face Value	10.0
PEG Ratio	-1.29

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Dipna Pharmachem Ltd

Competitors of Dipna Pharmachem Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
MPS Pharmaa Ltd	7.05 Cr.	3.69	4.33/3.05		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	51.9 Cr.	70.0	94.9/32.1	17.6	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	39.6 Cr.	27.0	29.0/8.74	40.4	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	76.2 Cr.	101	155/79.0	12.3	55.4	0.00 %	14.4 %	15.5 %	10.0
Industry Average	17,471.89 Cr	1,089.07		42.69	185.80	0.36%	16.00%	16.32%	6.27

All Competitor Stocks of Dipna Pharmachem Ltd

Quarterly Result

Metric	Sep 2021	Mar 2022	Sep 2022	Mar 2023	Sep 2023	Mar 2024	Sep 2024
Sales	29	44	49	74	74	90	91
Expenses	28	42	48	73	73	88	89
Operating Profit	1	1	1	2	2	2	1
OPM %	3%	3%	2%	2%	2%	2%	2%
Other Income	0	0	0	0	0	0	0
Interest	0	0	0	1	1	1	1
Depreciation	0	0	0	0	0	0	0
Profit before tax	0	1	0	1	1	1	0
Tax %	25%	26%	26%	27%	27%	21%	26%
Net Profit	0	1	0	1	1	0	0
EPS in Rs	33.00	84.00	0.13	0.24	0.24	0.20	0.14

Last Updated: February 28, 2025, 12:04 pm

Below is a detailed analysis of the quarterly data for Dipna Pharmachem Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Sales, as of Sep 2024, the value is ₹91.00 Cr.. The value appears strong and on an upward trend. It has increased from 90.00 Cr. (Mar 2024) to ₹91.00 Cr., marking an increase of ₹1.00 Cr..
For Expenses, as of Sep 2024, the value is ₹89.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 88.00 Cr. (Mar 2024) to ₹89.00 Cr., marking an increase of ₹1.00 Cr..
For Operating Profit, as of Sep 2024, the value is ₹1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2024) to ₹1.00 Cr., marking a decrease of 1.00 Cr..
For OPM %, as of Sep 2024, the value is 2.00%. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 2.00%.
For Other Income, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
For Interest, as of Sep 2024, the value is ₹1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1.00 Cr..
For Depreciation, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
For Profit before tax, as of Sep 2024, the value is ₹0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2024) to ₹0.00 Cr., marking a decrease of 1.00 Cr..
For Tax %, as of Sep 2024, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 21.00% (Mar 2024) to 26.00%, marking an increase of 5.00%.
For Net Profit, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
For EPS in Rs, as of Sep 2024, the value is 0.14. The value appears to be declining and may need further review. It has decreased from ₹0.20 (Mar 2024) to 0.14, marking a decrease of ₹0.06.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 1:21 pm

Metric	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	17	20	30	31	73	100	164	181
Expenses	16	20	30	31	71	98	161	178
Operating Profit	0	0	0	0	2	2	3	3
OPM %	2%	2%	1%	1%	3%	2%	2%	2%
Other Income	0	0	0	0	0	0	0	0
Interest	0	0	0	0	1	1	2	2
Depreciation	0	0	0	0	0	0	0	0
Profit before tax	0	0	0	0	2	1	1	1
Tax %	14%	40%	0%	60%	26%	34%	24%
Net Profit	0	0	0	0	1	1	1	1
EPS in Rs	6.00	3.00	6.00	2.00	117.00	0.37	0.45	0.34
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2022-2023	2023-2024
YoY Net Profit Growth (%)	0.00%	0.00%
Change in YoY Net Profit Growth (%)	0.00%	0.00%

Dipna Pharmachem Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 2 years from 2022-2023 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	%
5 Years:	52%
3 Years:	74%
TTM:	22%

Compounded Profit Growth
10 Years:	%
5 Years:	105%
3 Years:	279%
TTM:	-30%

Stock Price CAGR
10 Years:	%
5 Years:	%
3 Years:	%
1 Year:	15%

Return on Equity
10 Years:	%
5 Years:	7%
3 Years:	7%
Last Year:	4%

Last Updated: Unknown

Balance Sheet

Last Updated: December 14, 2024, 1:50 pm

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	0.04	0.04	0.04	0.04	0.04	12	24	24
Reserves	0	0	1	1	2	12	13	14
Borrowings	5	6	10	12	10	16	19	17
Other Liabilities	6	8	8	12	24	37	76	78
Total Liabilities	11	14	18	25	36	78	133	133
Fixed Assets	0	0	0	0	0	0	0	0
CWIP	0	0	0	0	0	0	0	0
Investments	0	0	0	0	0	0	0	0
Other Assets	11	14	18	25	36	78	133	133
Total Assets	11	14	18	25	36	78	133	133

Below is a detailed analysis of the balance sheet data for Dipna Pharmachem Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹24.00 Cr..
For Reserves, as of Sep 2024, the value is ₹14.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹13.00 Cr. (Mar 2024) to ₹14.00 Cr., marking an increase of 1.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹17.00 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from ₹19.00 Cr. (Mar 2024) to ₹17.00 Cr., marking a decrease of 2.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹78.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹76.00 Cr. (Mar 2024) to ₹78.00 Cr., marking an increase of 2.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹133.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹133.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
For CWIP, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
For Investments, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹133.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹133.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹133.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹133.00 Cr..

However, the Borrowings (17.00 Cr.) are higher than the Reserves (₹14.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	-3	-2	3	-21	-5
Cash from Investing Activity +	0	0	-0	-0	-0
Cash from Financing Activity +	3	2	-3	26	14
Net Cash Flow	0	0	-0	5	8

Free Cash Flow

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-5.00	-6.00	-10.00	-12.00	-8.00	-14.00	-16.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	132	160	134	176	135	104	69
Inventory Days	112	66	70	89	34	72	86
Days Payable	142	148	105	145	123	139	172
Cash Conversion Cycle	103	78	99	120	46	38	-17
Working Capital Days	116	114	119	150	59	126	96
ROCE %		8%	5%	3%	17%	9%	7%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2022	Mar 2023	Sep 2023	Mar 2024	Sep 2024
Promoters	66.56%	66.56%	57.19%	9.98%	9.98%
Public	33.45%	33.43%	42.81%	90.02%	90.02%
No. of Shareholders	1,110	992	1,078	1,807	2,652

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	0.90	260.55	333.40	6.91	16.86
Diluted EPS (Rs.)	0.90	260.55	333.40	6.91	16.86
Cash EPS (Rs.)	0.45	0.77	335.17	8.97	19.37
Book Value[Excl.RevalReserv]/Share (Rs.)	15.60	20.35	496.74	163.34	156.41
Book Value[Incl.RevalReserv]/Share (Rs.)	15.60	20.35	496.74	163.34	156.41
Revenue From Operations / Share (Rs.)	68.34	83.48	20787.26	8857.11	8725.29
PBDIT / Share (Rs.)	1.43	1.96	644.23	118.66	92.26
PBIT / Share (Rs.)	1.42	1.95	642.46	116.60	89.75
PBT / Share (Rs.)	0.59	1.15	449.80	15.71	17.15
Net Profit / Share (Rs.)	0.45	0.76	333.40	6.91	16.86
PBDIT Margin (%)	2.08	2.35	3.09	1.33	1.05
PBIT Margin (%)	2.07	2.33	3.09	1.31	1.02
PBT Margin (%)	0.86	1.38	2.16	0.17	0.19
Net Profit Margin (%)	0.66	0.91	1.60	0.07	0.19
Return on Networth / Equity (%)	2.89	3.74	67.11	4.23	10.78
Return on Capital Employeed (%)	6.82	6.06	44.39	9.58	57.38
Return On Assets (%)	0.81	1.17	3.22	0.09	0.32
Long Term Debt / Equity (X)	0.33	0.58	1.91	6.44	0.00
Total Debt / Equity (X)	0.51	0.65	5.86	21.74	17.45
Asset Turnover Ratio (%)	1.56	1.76	2.38	1.43	1.88
Current Ratio (X)	1.60	1.99	1.16	1.21	1.03
Quick Ratio (X)	1.15	1.50	0.95	0.85	0.71
Inventory Turnover Ratio (X)	0.00	0.00	10.03	4.90	0.00
Interest Coverage Ratio (X)	1.72	2.46	3.34	1.18	1.27
Interest Coverage Ratio (Post Tax) (X)	1.54	1.95	2.73	1.07	1.23
Enterprise Value (Cr.)	28.22	25.24	0.00	0.00	0.00
EV / Net Operating Revenue (X)	0.17	0.25	0.00	0.00	0.00
EV / EBITDA (X)	8.22	10.74	0.00	0.00	0.00
MarketCap / Net Operating Revenue (X)	0.13	0.15	0.00	0.00	0.00
Price / BV (X)	0.60	0.61	0.00	0.00	0.00
Price / Net Operating Revenue (X)	0.13	0.15	0.00	0.00	0.00
EarningsYield	0.04	0.06	0.00	0.00	0.00

After reviewing the key financial ratios for Dipna Pharmachem Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 24, the value is 0.90. This value is below the healthy minimum of 5. It has decreased from 260.55 (Mar 23) to 0.90, marking a decrease of 259.65.
For Diluted EPS (Rs.), as of Mar 24, the value is 0.90. This value is below the healthy minimum of 5. It has decreased from 260.55 (Mar 23) to 0.90, marking a decrease of 259.65.
For Cash EPS (Rs.), as of Mar 24, the value is 0.45. This value is below the healthy minimum of 3. It has decreased from 0.77 (Mar 23) to 0.45, marking a decrease of 0.32.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 15.60. It has decreased from 20.35 (Mar 23) to 15.60, marking a decrease of 4.75.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 15.60. It has decreased from 20.35 (Mar 23) to 15.60, marking a decrease of 4.75.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 68.34. It has decreased from 83.48 (Mar 23) to 68.34, marking a decrease of 15.14.
For PBDIT / Share (Rs.), as of Mar 24, the value is 1.43. This value is below the healthy minimum of 2. It has decreased from 1.96 (Mar 23) to 1.43, marking a decrease of 0.53.
For PBIT / Share (Rs.), as of Mar 24, the value is 1.42. This value is within the healthy range. It has decreased from 1.95 (Mar 23) to 1.42, marking a decrease of 0.53.
For PBT / Share (Rs.), as of Mar 24, the value is 0.59. This value is within the healthy range. It has decreased from 1.15 (Mar 23) to 0.59, marking a decrease of 0.56.
For Net Profit / Share (Rs.), as of Mar 24, the value is 0.45. This value is below the healthy minimum of 2. It has decreased from 0.76 (Mar 23) to 0.45, marking a decrease of 0.31.
For PBDIT Margin (%), as of Mar 24, the value is 2.08. This value is below the healthy minimum of 10. It has decreased from 2.35 (Mar 23) to 2.08, marking a decrease of 0.27.
For PBIT Margin (%), as of Mar 24, the value is 2.07. This value is below the healthy minimum of 10. It has decreased from 2.33 (Mar 23) to 2.07, marking a decrease of 0.26.
For PBT Margin (%), as of Mar 24, the value is 0.86. This value is below the healthy minimum of 10. It has decreased from 1.38 (Mar 23) to 0.86, marking a decrease of 0.52.
For Net Profit Margin (%), as of Mar 24, the value is 0.66. This value is below the healthy minimum of 5. It has decreased from 0.91 (Mar 23) to 0.66, marking a decrease of 0.25.
For Return on Networth / Equity (%), as of Mar 24, the value is 2.89. This value is below the healthy minimum of 15. It has decreased from 3.74 (Mar 23) to 2.89, marking a decrease of 0.85.
For Return on Capital Employeed (%), as of Mar 24, the value is 6.82. This value is below the healthy minimum of 10. It has increased from 6.06 (Mar 23) to 6.82, marking an increase of 0.76.
For Return On Assets (%), as of Mar 24, the value is 0.81. This value is below the healthy minimum of 5. It has decreased from 1.17 (Mar 23) to 0.81, marking a decrease of 0.36.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.33. This value is within the healthy range. It has decreased from 0.58 (Mar 23) to 0.33, marking a decrease of 0.25.
For Total Debt / Equity (X), as of Mar 24, the value is 0.51. This value is within the healthy range. It has decreased from 0.65 (Mar 23) to 0.51, marking a decrease of 0.14.
For Asset Turnover Ratio (%), as of Mar 24, the value is 1.56. It has decreased from 1.76 (Mar 23) to 1.56, marking a decrease of 0.20.
For Current Ratio (X), as of Mar 24, the value is 1.60. This value is within the healthy range. It has decreased from 1.99 (Mar 23) to 1.60, marking a decrease of 0.39.
For Quick Ratio (X), as of Mar 24, the value is 1.15. This value is within the healthy range. It has decreased from 1.50 (Mar 23) to 1.15, marking a decrease of 0.35.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 4. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Interest Coverage Ratio (X), as of Mar 24, the value is 1.72. This value is below the healthy minimum of 3. It has decreased from 2.46 (Mar 23) to 1.72, marking a decrease of 0.74.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 1.54. This value is below the healthy minimum of 3. It has decreased from 1.95 (Mar 23) to 1.54, marking a decrease of 0.41.
For Enterprise Value (Cr.), as of Mar 24, the value is 28.22. It has increased from 25.24 (Mar 23) to 28.22, marking an increase of 2.98.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 0.17. This value is below the healthy minimum of 1. It has decreased from 0.25 (Mar 23) to 0.17, marking a decrease of 0.08.
For EV / EBITDA (X), as of Mar 24, the value is 8.22. This value is within the healthy range. It has decreased from 10.74 (Mar 23) to 8.22, marking a decrease of 2.52.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 0.13. This value is below the healthy minimum of 1. It has decreased from 0.15 (Mar 23) to 0.13, marking a decrease of 0.02.
For Price / BV (X), as of Mar 24, the value is 0.60. This value is below the healthy minimum of 1. It has decreased from 0.61 (Mar 23) to 0.60, marking a decrease of 0.01.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 0.13. This value is below the healthy minimum of 1. It has decreased from 0.15 (Mar 23) to 0.13, marking a decrease of 0.02.
For EarningsYield, as of Mar 24, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 23) to 0.04, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Dipna Pharmachem Ltd as of March 11, 2025 is: ₹17.43

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 11, 2025, Dipna Pharmachem Ltd is Undervalued by 31.05% compared to the current share price 13.30

Intrinsic Value of Dipna Pharmachem Ltd as of March 11, 2025 is: 12.23

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 11, 2025, Dipna Pharmachem Ltd is Overvalued by 8.05% compared to the current share price 13.30

Last 5 Year EPS CAGR: -29.84%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has shown consistent growth in sales (77.00 cr) and profit (0.63 cr) over the years.	The stock has a low average ROCE of 7.00%, which may not be favorable. The stock has a high average Working Capital Days of 111.43, which may not be favorable. The stock has a high average Cash Conversion Cycle of 66.71, which may not be favorable. The company has higher borrowings (11.88) compared to reserves (5.38), which may suggest financial risk.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dipna Pharmachem Ltd:
1. Net Profit Margin: 0.66%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 6.82% (Industry Average ROCE: 15.87%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 2.89% (Industry Average ROE: 15.78%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 1.54
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.15
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 38.4 (Industry average Stock P/E: 34.22)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.51
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Dipna Pharmachem Ltd. is a Public Limited Listed company incorporated on 19/07/2011 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24100GJ2011PLC066400 and registration number is 066400. Currently company belongs to the Industry of Pharmaceuticals. Company's Total Operating Revenue is Rs. 164.34 Cr. and Equity Capital is Rs. 24.05 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad Gujarat 380055	info@dipnapharmachem.com http://www.dipnapharmachem.com

Management
Name	Position Held
Mr. Keyur Dipakkumar Shah	Managing Director
Ms. Dipna Keyur Shah	Non Executive Director
Mr. Nandish Shaileshbhai Jani	Independent Director
Mr. Jitendra Pradipbhai Parmar	Independent Director

FAQ

What is the latest intrinsic value of Dipna Pharmachem Ltd?

The latest intrinsic value of Dipna Pharmachem Ltd as on 11 March 2025 is ₹17.43, which is 31.05% higher than the current market price of 13.30, indicating the stock is undervalued by 31.05%. The intrinsic value of Dipna Pharmachem Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹31.9 Cr. and recorded a high/low of ₹16.6/6.40 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹14 Cr and total liabilities of ₹133 Cr.

What is the Market Cap of Dipna Pharmachem Ltd?

The Market Cap of Dipna Pharmachem Ltd is 31.9 Cr..

What is the current Stock Price of Dipna Pharmachem Ltd as on 11 March 2025?

The current stock price of Dipna Pharmachem Ltd as on 11 March 2025 is ₹13.3.

What is the High / Low of Dipna Pharmachem Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Dipna Pharmachem Ltd stocks is ₹16.6/6.40.

What is the Stock P/E of Dipna Pharmachem Ltd?

The Stock P/E of Dipna Pharmachem Ltd is 38.4.

What is the Book Value of Dipna Pharmachem Ltd?

The Book Value of Dipna Pharmachem Ltd is 15.8.

What is the Dividend Yield of Dipna Pharmachem Ltd?

The Dividend Yield of Dipna Pharmachem Ltd is 0.00 %.

What is the ROCE of Dipna Pharmachem Ltd?

The ROCE of Dipna Pharmachem Ltd is 7.05 %.

What is the ROE of Dipna Pharmachem Ltd?

The ROE of Dipna Pharmachem Ltd is 3.52 %.

What is the Face Value of Dipna Pharmachem Ltd?

The Face Value of Dipna Pharmachem Ltd is 10.0.